07756 859468

Dr Tim Ambrose

Consultant Gastroenterologist
MBChB, FRCP, DPhil

Dr Tim Ambrose

Dr Tim Ambrose (MBChB, FRCP, DPhil) is a Consultant Gastroenterologist at Oxford University Hospitals NHS Foundation Trust and Nuffield Health, The Manor Hospital, Oxford.

Dr Ambrose has expertise in all aspects of general gastroenterology including anaemia, diarrhoea, constipation, abdominal pain, reflux, swallowing difficulties, nausea/vomiting and weight loss. His subspecialty interests lie in inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and clinical nutrition (including coeliac disease, short bowel syndrome and stoma dysfunction). He is accredited for diagnostic and therapeutic gastroscopy and colonoscopy.

Dr Ambrose provides patient-focused consultations with shared agreement on investigations and treatment strategies. Politeness, communication and explanation have been consistent themes in patient feedback.

Dr Ambrose qualified in medicine from The University of Edinburgh and completed his training in Gastroenterology in Oxford and the wider Thames Valley region. He undertook a Fellowship in Intestinal Rehabilitation at St Mark’s Hospital, London, and in Intestinal Transplantation at Addenbrooke’s Hospital, Cambridge (2014-2015). He was awarded his DPhil from The University of Oxford (2018) and for his thesis, he was awarded a Letter of Commendation.

Dr Ambrose has ongoing academic interests related to his areas of practice and has peer-reviewed for a number of relevant journals. He enjoys teaching and training others and has been the Training Lead for gastroenterology trainees in Oxford since 2019. He lectures on the graduate entry medical student teaching programme for Gastroenterology.

Dr Ambrose sits on the Small Bowel & Nutrition committee of the British Society of Gastroenterology and on the committee of the British Association for Parenteral and Enteral Nutrition Medical section. He is also a member of the European Crohn’s and Colitis Organisation. He is on the specialist register with the General Medical Council (GMC).

 

Relevant publications:

  1. Mercer C, Crawford A, Shapiro S, Allan PJ, Ambrose T. Anticoagulation and antiplatelet therapy in short bowel syndrome: a systematic review. Intestinal Failure 2024;1:100007
  2. Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2023;72(3):433-442. PMID: 36171080
  3. Wong D, Matini L, Kormilitzin A, Kantschuster R, Simadibrata DM, Lyden S, Wilson J, Brain OA, Palmer R, Ambrose T, Satsangi J, South M, Geddes J, Bodger K, Travis SPL, Walsh A. Patient-reported outcomes: the ICHOM standard set for inflammatory bowel disease in real-life practice helps quantify deficits in current care. J Crohns Colitis 2022;16(12):1874-81. PMID: 35868223
  4. Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE, Oxford IBD Cohort Study Investigators, Lindsay JO, Vega R, Thomas-Gibson S, Warusavitarne J, Wilson A, Graham TA, Hart A. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut 2022;71(4):705-715. PMID: 33990383
  5. McGregor CC, Adams A, Sadler R, Arancibia-Carcamo CV, Palmer R, Ambrose T, Brain O, Walsh A, Klenerman P, Travis SP, Croft NM, Lindsay JO, Satsangi J. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalance: UK experience in the 2020 pandemic. Gut 2021;70(12):2398-400. PMID: 33579788
  6. Allan PJ, Ambrose T, Mountford C, Bond A, Donnellan C, Boyle R, Calvert C, Cernat E, Clarke E, Copper SC, Donnelly S, Evans B, Glynn M, Hewett R, Holohan AS, Leitch EF, Louis-Auguste J, Mehta S, Naik S, Nighingale J, Rafferty G, Rodrigues A, Sharkey L, Small M, Teubner A, Urs A, Wyer N, Lal S. COVID-19 infection in patients with intestinal failure: UK experience. Journal of Parenteral and Enteral Nutrition 2021;45(6):1369-75. PMID: 33586170
  7. Ambrose T, De Silva A, Naghibi M, Saunders J, Smith TR, Coleman RL, Stroud M. Refeeding risks in patients requiring intravenous nutrition support: results of a two-centre, prospective, double-blind, randomised controlled trial. Clinical Nutrition ESPEN 2021;41:142-52. PMID: 33487258
  8. FitzPatrick MEB, Provine NM, Garner LC, Powell K, Amini A, Irwin S, Ferry H, Ambrose T, Friend P, Vrakas G, Reddy S, Soilleux E, Klenerman P, Allan PJ. Human intestinal tissue-resident memory CD8+ T cells comprise transcriptionally and functionally distinct subsets. Cell Reports 2021;34(3):108661. PMID: 33472060
  9. Ambrose T, Travis SPL, Allan PJ. Letter to the Editor – Reply – Intestinal transplantation and quality of life. Clinical Nutrition 2021;40(1):332-3. PMID: 33248873
  10. Ambrose T, Holdaway L, Smith A, Howe H, Vokes L, Vrakas G, Reddy S, Giele H, Travis SPL, Friend PJ, Allan PJ. The impact of intestinal transplantation on quality of life. Clinical Nutrition 2020;39(6):1958-1967. PMID: 31522787
  11. Ambrose T, Simmons A. Cannabis, cannabinoids and the endocannabinoid system: is there therapeutic potential for inflammatory bowel disease? Journal of Crohn’s and Colitis 2019;13(4):525-35. PMID: 30418525
  12. Louis-Auguste JR, Micallef C, Ambrose T, Upponi S, Butler AJ, Massey D, Middleton SJ, Russell N, Rutter CS, Sharkey LM, Woodward J, Gkrania-Klotsas E, Enoch DA. Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: case report and literature review. ID Cases 2018;12:76-79. PMID: 29942755
  13. Ambrose T#, Corridoni D#, Chapman T#, Simmons A (#Joint first authors). Emerging mechanisms of innate immunity and their translational potential in inflammatory bowel disease. Frontiers in Medicine 2018;5:32. PMID: 29515999. 
  14. Topan R, Ambrose T, Small M, Lightman E, Nightingale J, Gabe SM. Spinal infections among patients with long term central venous catheters for home parenteral nutrition: a descriptive case series. Nutrition in Clinical Practice2017;32(1):133-138. PMID: 27385770
  15. Ambrose T, Sharkey LM, Louis-Auguste J, Rutter CS, Duncan S, English S, Gkrania-Klotsas E, Carmichael A, Woodward JM, Russell N, Massey D, Butler A, Middleton SJ. Cytomegalovirus viraemia and rates of antiviral resistance following intestinal and multivisceral transplantation. Transplantation Proceedings 2016;48(2):492-6. PMID: 27109985
  16. Ambrose T, Sharkey L, Louis-Auguste J, Butler A, Massey D, Russell N, Pursglove S, Middleton SJ. Image of the month: Stomal cytomegalovirus infection following intestinal transplant. American Journal of Gastroenterology2015;110(11):1534. PMID: 26618415
  17. Ambrose T, Cullen S, Baker G, Smith M, Elia M, Leach R, De Silva A. Obesity – a window of opportunity to intervene? Characteristics and management of morbidly obese adult inpatients in three Trusts in Southern England. Clinical Medicine 2013;13(5):472-6. PMID: 24115704
  18. Ambrose T, Musa F, Simmons J, De Silva A. The role of full thickness jejunal biopsy in diagnosing inflammatory neuromuscular gastrointestinal conditions. American Journal of Gastroenterology 2012;107(11):1764-5. PMID: 23160306